CompletedPhase 3NCT03293524
Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
Studying Leber hereditary optic neuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GenSight Biologics
- Principal Investigator
- Nancy Newman, MDEmory University Hospital Atlanta, Georgia, United States, 30322
- Intervention
- GS010(genetic)
- Enrollment
- 98 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2018 – 2024
Study locations (13)
- Doheny Eye Center UCLA Pasadena, Pasadena, California, United States
- University of Colorado Health Eye Center, Aurora, Colorado, United States
- Emory Healthcare - The Emory Clinic, Atlanta, Georgia, United States
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Wills Eye Institute - Ocular Oncology Service, Philadelphia, Pennsylvania, United States
- Vanderbilt Eye Institute, Nashville, Tennessee, United States
- Universitair Ziekenhuis Gent, Ghent, Belgium
- CHNO Les Quinze Vingts, Paris, France
- IRCCS Istituto delle Scienze Neurologiche di Bologna UOC Clinica Neurologica, Bologna, Italy
- Hospital Universitario Ramon y Cajal, Madrid, Spain
- Taipei Veterans General Hospital, Taipei, Taiwan
- Moorfields Eye Hospital, London, Greater London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03293524 on ClinicalTrials.govOther trials for Leber hereditary optic neuropathy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT07406854A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 MutationWuhan Neurophth Biotechnology Limited Company
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05293626Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 MutationsNeurophth Therapeutics Inc
- RECRUITINGNANCT06682819Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)Hôpital Necker-Enfants Malades
- ENROLLING BY INVITATIONNCT06376279Genetic Diagnosis in Inborn Errors of MetabolismRegion Stockholm